{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:59:01Z","timestamp":1794844741193,"version":"4.9.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>A difference between involved and uninvolved free light chains (dFLC) \u2265180 mg\/L is part of the 2012 Mayo staging system for amyloid light chain (AL) amyloidosis given its negative impact on overall survival (OS). However, none of the 758 patients evaluated to develop and validate this staging system received bortezomib or daratumumab-containing regimens. Over the past 2 decades, cyclophosphamide-bortezomib-dexamethasone (CyBorD) and, more recently, daratumumab-CyBorD (DaraCyBorD) have become cornerstone treatments for AL amyloidosis, demonstrating high efficacy in rapidly normalizing FLC levels. We hypothesized that, in patients with newly diagnosed AL amyloidosis treated with bortezomib- and daratumumab-based regimens, a baseline high FLC burden may no longer predict adverse prognosis. In this retrospective, multicenter study of 223 patients with newly diagnosed AL amyloidosis treated with CyBorD or DaraCyBorD therapy, we investigated (1) the association between baseline involved FLC and dFLC hematologic response at 28 days and 3, 6, 9, and 12 months after the commencement of therapy; (2) the OS of patients with baseline low (&amp;lt;180 mg\/L), medium (180-400 mg\/L), and high (&amp;gt;400 mg\/L) dFLC; and (3) the prognostic value of bone marrow plasma cell burden in determining response to CyBorD or DaraCyBorD therapy and OS and, finally, the prognostic value of the 2012 Mayo staging system in the CyBorD and DaraCyBorD cohorts. Our findings suggest that a dFLC of &amp;gt;180 mg\/L no longer holds prognostic value in the era of CyBorD\/DaraCyBorD\u2013based AL amyloidosis therapy and question the utility of the Mayo 2012 staging system in the era of highly effective chemoimmunotherapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015528","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T21:16:56Z","timestamp":1746047816000},"page":"3771-3779","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-7831","authenticated-orcid":false,"given":"Brendan","family":"Saunders","sequence":"first","affiliation":[{"name":"1Amyloidosis Program, Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"2Department of Clinical Therapeutics, National Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"2Department of Clinical Therapeutics, National Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Boullt","sequence":"additional","affiliation":[{"name":"1Amyloidosis Program, Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Evans","sequence":"additional","affiliation":[{"name":"1Amyloidosis Program, Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"2Department of Clinical Therapeutics, National Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"2Department of Clinical Therapeutics, National Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[{"name":"1Amyloidosis Program, Division of Hematology, Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"3Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"},{"name":"4Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"1","key":"2025081209363714300_bib1","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"6","key":"2025081209363714300_bib2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2025081209363714300_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","article-title":"Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases","volume":"68","author":"Kyle","year":"1986","journal-title":"Blood"},{"issue":"18","key":"2025081209363714300_bib4","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"19","key":"2025081209363714300_bib5","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"2025081209363714300_bib6","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2004-01-0390","article-title":"Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"104","author":"Dispenzieri","year":"2004","journal-title":"Blood"},{"issue":"9371","key":"2025081209363714300_bib7","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"2025081209363714300_bib8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"9","key":"2025081209363714300_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025081209363714300_bib10","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2016-08-730978","article-title":"The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity","volume":"129","author":"Oliva","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2025081209363714300_bib11","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2025081209363714300_bib12","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/j.clml.2024.01.013","article-title":"Healthcare resource utilization and cost-of-illness in systemic light chain (AL) amyloidosis in Europe: results from the real-world, restrospective EMN23 study","volume":"24","author":"Jaccard","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2025081209363714300_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2025081209363714300_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ajh.27179","article-title":"Reduced early mortality with daratumumab-based frontline therapy in AL amyloidosis: a retrospective cohort study","volume":"99","author":"Chakraborty","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2025081209363714300_bib15","first-page":"1598","article-title":"Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis - analysis of a uniformly treated cohort of 1,275 patients","volume":"109","author":"Khwaja","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"2025081209363714300_bib16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2018-10-875252","article-title":"Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay","volume":"133","author":"Muchtar","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2025081209363714300_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2025081209363714300_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.18.01398","article-title":"Validation of Mayo clinic staging system for light chain amyloidosis with high-sensitivity troponin","volume":"37","author":"Kumar","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025081209363714300_bib19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"34","key":"2025081209363714300_bib20","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol"},{"issue":"36","key":"2025081209363714300_bib21","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025081209363714300_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.21948","article-title":"Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"19","key":"2025081209363714300_bib23","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2025081209363714300_bib24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2024-205077","article-title":"Subcutaneous daratumumab (DARA) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: overall survival and final major organ deterioration progression-free survival results from the phase 3 Andromeda study","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3771\/2404005\/blooda_adv-2024-015528-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/3771\/2404005\/blooda_adv-2024-015528-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T13:36:45Z","timestamp":1755005805000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/3771\/537057\/Predictive-value-of-free-light-chain-burden-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":24,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015528","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,7,25]]}}}